Sector Expert: Saeid Babaei
Saeid Babaei, Ph.D., chairman of BriaCell, holds executive positions in multiple biotech companies. He is CEO of AbCelex, which recently obtained investment from a top agtech/biotech venture capitalist and was vice president of Lorus Therapeutics, where he was responsible for a large turnaround and the out-licensing of a Phase 3 cancer immuno-oncology program to a private equity firm. He was director of corporate development at Northern Therapeutics, which was successfully partnered to United Therapeutics.
Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. In this interview with The Life Sciences Report, BriaCell Therapeutics Corp. executives Joseph Wagner, Charles Wiseman and Saeid Babaei describe their company's new therapeutic, which has generated stunning results in early trials, making "breakthrough" designation by the FDA a realistic possibility.